Characterization of the cytochrome P450 enzymes and enzyme kinetic parameters for metabolism of BVT.2938 using different in vitro systems

被引:6
作者
Baranczewski, P [1 ]
Edlund, PO [1 ]
Postlind, H [1 ]
机构
[1] Biovitrum AB, Preclin R&D, SE-11276 Stockholm, Sweden
关键词
drug metabolism; enzyme kinetics; CYP2D6/CYP2D2; dark Agouti rats;
D O I
10.1016/j.jpba.2005.09.006
中图分类号
O65 [分析化学];
学科分类号
070302 [分析化学]; 081704 [应用化学];
摘要
An important step in the drug development process is identification of enzymes responsible for metabolism of drug candidates and determination of enzyme kinetic parameters. These data are used to increase understanding of the pharmacokinetics and possible metabolic-based drug interactions of drug candidates. The aim of the present study was to characterize the cytochrome P450 enzymes and enzyme kinetic parameters for metabolism of BVT.2938 [1-(3-{2-vertical bar(2-ethoxy-3-pyridinyi)oxylethoxyl-2-pyrazinyl)-2(R)-methylpiperazine], a potent and selective 5HT2c-receptor agonist. The enzyme kinetic parameters were determined for formation of three main metabolites of BVT.2938 using human liver microsomes and expressed cytochrorne P450 (CYP) isoforms. The major metabolite was formed by hydroxylation of the pyridine ring (CLmt = 27 mu l/mg min), and was catalysed by both CYP2D6*1 and CYP1A1, with K values corresponding to 1.4 and 2.7 mu M, respectively. The results from enzyme kinetic studies were confirmed by incubation of BVT.2938 in the presence of the chemical inhibitor of CYP2D6*1, quinidine. Quinidine inhibited the formation of the major metabolite by approximately 90%. Additionally, studies with recombinant expressed CYP isoforms from rat indicated that formation of the major metabolite of BVT.2938 was catalysed by CYP2D2. This result was further confirmed by experiments with liver slices from different rat strains, where the formation of the metabolite correlated with phenotype of CYP2D2 isoform (Sprague-Dawley male, extensive-Dark Agouti male, intermediate; Dark Agouti female, poor metabolizer). The present study showed that the major metabolite of BVT.2938 is formed by hydroxylation of the pyridine ring and catalysed by CYP2D6*1. CYP1A1 is also involved in this reaction and its role in extra-hepatic metabolism of BVT.2938 might be significant. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:1121 / 1130
页数:10
相关论文
共 19 条
[1]
ANIMAL MODELING OF HUMAN POLYMORPHIC DRUG OXIDATION - THE METABOLISM OF DEBRISOQUINE AND PHENACETIN IN RAT INBRED STRAINS [J].
ALDABBAGH, SG ;
IDLE, JR ;
SMITH, RL .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1981, 33 (03) :161-164
[2]
Åsberg A, 2003, DRUGS, V63, P367
[3]
AN EVALUATION OF CYTOCHROME-P450 ISOFORM ACTIVITIES IN THE FEMALE DARK AGOUTI (DA) RAT - RELEVANCE TO ITS USE AS A MODEL OF THE CYP2D6 POOR METABOLIZER PHENOTYPE [J].
BARHAM, HM ;
LENNARD, MS ;
TUCKER, GT .
BIOCHEMICAL PHARMACOLOGY, 1994, 47 (08) :1295-1307
[4]
The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective [J].
Bjornsson, TD ;
Callaghan, JT ;
Einolf, HJ ;
Fischer, V ;
Gan, L ;
Grimm, S ;
Kao, J ;
King, SP ;
Miwa, G ;
Ni, L ;
Kumar, G ;
McLeod, J ;
Obach, RS ;
Roberts, S ;
Roe, A ;
Shah, A ;
Snikeris, F ;
Sullivan, JT ;
Tweedie, D ;
Vega, JM ;
Walsh, J ;
Wrighton, SA .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (07) :815-832
[5]
Human extrahepatic cytochromes P450: Function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts [J].
Ding, XX ;
Kaminsky, LS .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2003, 43 :149-173
[6]
Pharmacogenomics: Translating functional genomics into rational therapeutics [J].
Evans, WE ;
Relling, MV .
SCIENCE, 1999, 286 (5439) :487-491
[7]
Drug therapy - Pharmacogenomics - Drug disposition, drug targets, and side effects [J].
Evans, WE ;
McLeod, HL .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) :538-549
[8]
Cytochrome P-450 3A4: Regulation and role in drug metabolism [J].
Guengrich, FP .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :1-17
[9]
Obesity drug pipeline not so fat [J].
Gura, T .
SCIENCE, 2003, 299 (5608) :849-852
[10]
Catalytic specificity of CYP2D isoforms in rat and human [J].
Hiroi, T ;
Chow, T ;
Imaoka, S ;
Funae, Y .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (09) :970-976